title: The efficacy and safety of probiotics intervention in preventing conversion of impaired glucose tolerance to diabetes: study protocol for a randomized, double-blinded, placebo controlled trial of the Probiotics Prevention Diabetes Programme (PPDP).
abstract: BACKGROUND
  Alterations in intestinal microbiota correlate with risk of development of obesity and type 2 diabetes. Probiotics have been suggested to play an important role in the management of dysglycemia, although the evidence is limited. In this study, we aim to explore the efficacy and safety of probiotics intervention in preventing type 2 diabetes in Chinese patients with impaired glucose tolerance.
  
  
  METHODS
  A 24-month randomized intervention is conducted from January 2014 to December 2016. The target sample size for intervention is 200 middle-aged men and women aged 30-65 year-old with impaired glucose tolerance. Participants with persistent impaired glucose tolerance were assigned to group A (tablet A) and B (tablet B) in sequential order. The participants and investigators were blinded to the assignment. The primary outcome is development of diabetes. The secondary outcome measures include body composition, biochemical variables and the safety of the probiotics.
  
  
  CONCLUSIONS
  The results from this trial will provide the evidence on the efficacy and safety of probiotics administration in preventing conversion of impaired glucose tolerance to diabetes in a Chinese context.
  
  
  BACKGROUND
  ChiCTRTRC13004024.
authors.affiliation: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Jimo Road 150, Shanghai, China. yanqun120811@126.com.
authors.forename: Qun
authors.initials: Q
authors.lastname: Yan
authors.affiliation: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Jimo Road 150, Shanghai, China. lixu@medmail.com.cn.
authors.forename: Xu
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Jimo Road 150, Shanghai, China. fengbo@medmail.com.cn.
authors.forename: Bo
authors.initials: B
authors.lastname: Feng
mesh_terms: D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000178:diet therapy*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000178:diet therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009747:Nutritional Physiological Phenomena; D011236:Prediabetic State / Q000097:blood / Q000178:diet therapy*; D019936:Probiotics / Q000627:therapeutic use*; D016896:Treatment Outcome